Calculating cancer costs in the EU

Author：  

Publisher： Adis International

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.666, 2012-01, pp. : 5-5

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Friction-Cost Method as an Alternative to the Human-Capital Approach in Calculating Indirect Costs

By Adis International Limited  

PharmacoEconomics, Vol. 23, Iss. 2, 2005-01 ,pp. : 103-104

Adis International

Access to resources Recommend Favorite

Cancer drug costs discussed

By  

Inpharma, Vol. 1, Iss. 1460, 2004-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

ESRD costs and burden reduced with losartan in the EU

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 388, 2002-01 ,pp. : 3-4

Adis International

Access to resources Recommend Favorite

Benzodiazepine-related fall costs staggering in the EU

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 428, 2003-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

ESRD costs and burden reduced with losartan in the EU

By  

Inpharma, Vol. 1, Iss. 1362, 2002-01 ,pp. : 5-6

Adis International

Access to resources Recommend Favorite